 |
78 Diseases |  |
2 Trials |
|
2 Trials |  |
176 News |  |
| 12» |
- | oxandrolone / Generic mfg.
Journal: Use of testosterone replacement therapy in the rehabilitation of patients with intensive care unit-associated weakness and hospital-associated deconditioning: the Singapore General Hospital rehabilitation experience. (Pubmed Central) - Nov 13, 2024
TRT has the potential to be used as a useful adjunct to standard rehabilitation in enhancing functional recovery in critically ill patients. A multidisciplinary approach would ensure that suitable patients benefit from optimal nutrition, optimal rehabilitation and synergistic testosterone therapy in a clinically sound and resource-efficient fashion.
- | oxandrolone / Generic mfg.
Journal: Tempol, a superoxide dismutase mimetic, inhibits Wallerian degeneration following spinal cord injury by preventing glutathione depletion and aldose reductase activation. (Pubmed Central) - Sep 18, 2024
Interestingly, methylprednisolone, oxandrolone, and clenbuterol, which are known to spare axonal tracts after spinal cord injury, were equally effective in inhibiting polyol pathway activation. These results suggest that prevention of AR activation is a common target of many disparate post-SCI interventions.
- | Journal: Changing trends in anabolic-androgenic steroid use within Scottish prisons: Detection, prevalence, and quantitation. (Pubmed Central) - Aug 20, 2024
Most AAS samples were tablets (77.0%), although they were also detected in powders, herbal material, e-cigarettes, and a fragmented soap bar-type sample. There was a large variation in the concentration of AASs in the tablets and powders seized from the Scottish prisons, demonstrating AASs are another highly variable component of the polydrug use situation in prisons, the effects of which need to be examined further.
- | oxandrolone / Generic mfg., pentoxifylline / Generic mfg.
Journal: Recalcitrant lipodermatosclerosis with ulceration treated with oxandrolone and pentoxifylline. (Pubmed Central) - Jul 18, 2024
There was a large variation in the concentration of AASs in the tablets and powders seized from the Scottish prisons, demonstrating AASs are another highly variable component of the polydrug use situation in prisons, the effects of which need to be examined further. No abstract available
- | oxandrolone / Generic mfg.
Enrollment change, Trial completion date, Trial termination: Use of Oxandrolone to Promote Growth in Infants With HLHS (clinicaltrials.gov) - May 23, 2024
P1/2, N=34, Terminated, Sponsor: Carelon Research
No abstract available N=100 --> 34 | Trial completion date: Jun 2024 --> Sep 2023 | Suspended --> Terminated; FDA withdrawal of Oxandrin NDA and generic ANDAs
- || oxandrolone / Generic mfg., propranolol / Generic mfg.
Review, Journal: Nutrition in Pediatric Burns. (Pubmed Central) - May 15, 2024
Lastly, the catabolic state of acute burns is addressed through early excision and grafting and implementation of various pharmacologic agents, including growth hormone, insulin-like growth factor-1, insulin-like growth factor-binding protein-3, insulin, propranolol, and oxandrolone. Through a multipronged approach to nutrition, pediatric burn patients are provided the substrates for successful recovery and rehabilitation.
- | oxandrolone / Generic mfg.
Retrospective data, Journal: Administration and effects of beta blockers and oxandrolone in severely burned adults: a post hoc analysis of the RE-ENERGIZE trial. (Pubmed Central) - Apr 23, 2024
P3
Our findings found mixed associations between outcomes and the use of BB and OX in adult burn patients, with lower acute and 6-month-mortality with BB and longer times to discharge with OX. Further research into these pharmacological modulators of the pathophysiological response to severe burn injury is indicated.
- bimagrumab (BYM338) / Novartis, MorphoSys, Eli Lilly
EFFICACY OF PHARMACOLOGICAL TREATMENT IN INCLUSION BODY MYOSITIS: A SYSTEMATIC REVIEW (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_2549;
We observed inconsistency of outcome measures across trials. More randomized controlled trials are needed, of adequate size and duration, and using a standardized set of outcome measures.
- | oxandrolone / Generic mfg.
Trial primary completion date: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Mar 2, 2024
P=N/A, N=116, Active, not recruiting, Sponsor: University of Southern California
More randomized controlled trials are needed, of adequate size and duration, and using a standardized set of outcome measures. Trial primary completion date: Dec 2023 --> May 2024
- || bortezomib / Generic mfg., oxandrolone / Generic mfg.
Review, Journal: Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities. (Pubmed Central) - Jan 4, 2024
Future research should focus on expanding knowledge on underlying pathophysiological mechanisms of PICS to identify and validate other potential endotypes of chronic critical illness and subsequent treatable traits. There is unlikely to be a universal treatment for PICS, and a multimodal, timely, and personalised therapeutic strategy will be needed to improve outcomes for this growing cohort of patients.
- | oxandrolone / Generic mfg.
Trial completion date, Trial primary completion date: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Dec 31, 2023
P=N/A, N=116, Active, not recruiting, Sponsor: University of Southern California
- | oxandrolone / Generic mfg.
Journal: Online information and availability of three doping substances (anabolic agents) in sports: role of pharmacies. (Pubmed Central) - Dec 19, 2023
The aim of this study was to estimate the availability and accessible information on the Internet about the sale of three doping substances (oxandrolone, DHEA, androstenedione)...It would be advisable for these products to be sold through pharmacies, to guarantee their quality and provide evidence-based information on their safe use, benefits and risks, and only with a prescription. Athletes should be encouraged to consult health professionals about those supplements suitable for their type of training and sports objectives.
- | oxandrolone / Generic mfg.
Enrollment open: Oxandrolone Multiligament Knee (clinicaltrials.gov) - Nov 22, 2023
P4, N=60, Recruiting, Sponsor: George F. Hatch
Athletes should be encouraged to consult health professionals about those supplements suitable for their type of training and sports objectives. Not yet recruiting --> Recruiting
- | oxandrolone / Generic mfg.
Enrollment closed: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Nov 18, 2023
P=N/A, N=116, Active, not recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | metformin / Generic mfg., oxandrolone / Generic mfg.
Journal: A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) models. (Pubmed Central) - Nov 10, 2023
Two of these candidates, metformin and oxandrolone, were further investigated in SMA cellular and animal models, which highlighted that these compounds do not have the same ameliorative effects on SMA phenotypes as prednisolone; however, a number of other important drug targets remain. Overall, our work further supports the usefulness of prednisolone's potential as a second-generation therapy for SMA, identifies a list of potential SMA drug treatments and highlights improvements for future transcriptomic-based drug repositioning studies in SMA.
- | oxandrolone / Generic mfg.
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date: Placebo Versus Oxandrolone Supplementation in Trauma (clinicaltrials.gov) - Aug 14, 2023
P3, N=0, Withdrawn, Sponsor: Sunnybrook Health Sciences Centre
Overall, our work further supports the usefulness of prednisolone's potential as a second-generation therapy for SMA, identifies a list of potential SMA drug treatments and highlights improvements for future transcriptomic-based drug repositioning studies in SMA. N=86 --> 0 | Trial completion date: Feb 2025 --> Aug 2023 | Initiation date: May 2023 --> May 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2024 --> Aug 2023
- | oxandrolone / Generic mfg.
Journal: Normalization of puberty and adult height in girls with Turner syndrome: results of the Swedish Growth Hormone trials initiating transition into adulthood. (Pubmed Central) - Aug 6, 2023
N=86 --> 0 | Trial completion date: Feb 2025 --> Aug 2023 | Initiation date: May 2023 --> May 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2024 --> Aug 2023 Treatment given were recombinant human (rh)GH (Genotropin Kabi Peptide Hormones, Sweden) 33 or 67
- oxandrolone / Generic mfg.
A Case of Anabolic Androgenic Steroid Drug-Induced Liver Injury (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1513;
Treatment given were recombinant human (rh)GH (Genotropin Kabi Peptide Hormones, Sweden) 33 or 67 Case Description/ A 31-year-old male with a distant history of intravenous drug use and alcohol use had been injecting a street preparation of testosterone cypionate and taking an anabolic androgenic steroid called
- | oxandrolone / Generic mfg.
Trial suspension: Use of Oxandrolone to Promote Growth in Infants With HLHS (clinicaltrials.gov) - Jul 12, 2023
P1/2, N=100, Suspended, Sponsor: HealthCore-NERI
Case Description/ A 31-year-old male with a distant history of intravenous drug use and alcohol use had been injecting a street preparation of testosterone cypionate and taking an anabolic androgenic steroid called Recruiting --> Suspended
- | oxandrolone / Generic mfg.
New P4 trial: Oxandrolone Multiligament Knee (clinicaltrials.gov) - Jun 7, 2023
P4, N=60, Not yet recruiting, Sponsor: George F. Hatch
- | oxandrolone / Generic mfg.
Trial initiation date: Placebo Versus Oxandrolone Supplementation in Trauma (clinicaltrials.gov) - Apr 13, 2023
P3, N=86, Not yet recruiting, Sponsor: Sunnybrook Health Sciences Centre
Recruiting --> Suspended Initiation date: Aug 2022 --> May 2023
- | oxandrolone / Generic mfg.
Trial completion date, Trial primary completion date: Use of Oxandrolone to Promote Growth in Infants With HLHS (clinicaltrials.gov) - Feb 17, 2023
P1/2, N=100, Recruiting, Sponsor: HealthCore-NERI
Initiation date: Aug 2022 --> May 2023 Trial completion date: May 2023 --> Jun 2024 | Trial primary completion date: Nov 2022 --> Dec 2023
- | oxandrolone / Generic mfg.
Phase classification, Trial completion date, Trial primary completion date: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Feb 10, 2023
P=N/A, N=116, Recruiting, Sponsor: University of Southern California
Trial completion date: May 2023 --> Jun 2024 | Trial primary completion date: Nov 2022 --> Dec 2023 Phase classification: P2 --> P=N/A | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- | oxandrolone / Generic mfg.
New P3 trial: Placebo Versus Oxandrolone Supplementation in Trauma (clinicaltrials.gov) - Aug 26, 2022
P3, N=86, Not yet recruiting, Sponsor: Sunnybrook Health Sciences Centre
- | oxandrolone / Generic mfg.
Enrollment open, Enrollment change: Use of Oxandrolone to Promote Growth in Infants With HLHS (clinicaltrials.gov) - Jun 3, 2022
P1/2, N=100, Recruiting, Sponsor: HealthCore-NERI
Phase classification: P2 --> P=N/A | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Active, not recruiting --> Recruiting | N=25 --> 100
- | oxandrolone / Generic mfg.
Trial completion date, Trial primary completion date: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Sep 17, 2021
P2, N=144, Recruiting, Sponsor: University of Southern California
Active, not recruiting --> Recruiting | N=25 --> 100 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022
- | oxandrolone / Generic mfg.
Enrollment closed, Enrollment change: Use of Oxandrolone to Promote Growth in Infants With HLHS (clinicaltrials.gov) - Aug 25, 2021
P1/2, N=25, Active, not recruiting, Sponsor: HealthCore-NERI
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022 Recruiting --> Active, not recruiting | N=100 --> 25
- | oxandrolone / Generic mfg.
Trial completion, Surgery: Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants (clinicaltrials.gov) - Jan 29, 2020
P1, N=20, Completed, Sponsor: University of Utah
Recruiting --> Active, not recruiting | N=100 --> 25 Active, not recruiting --> Completed
- | oxandrolone / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Use of Oxandrolone to Promote Growth in Infants With HLHS (clinicaltrials.gov) - Jan 21, 2020
P1/2, N=100, Recruiting, Sponsor: New England Research Institutes
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Sep 2022 --> May 2023 | Trial primary completion date: Mar 2022 --> Nov 2022
- | Trial completion date, Trial termination: Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation (clinicaltrials.gov) - Nov 30, 2019
P2/3, N=1126, Terminated, Sponsor: The University of Texas Medical Branch, Galveston
Trial completion date: Sep 2018 --> Jul 2019 | Recruiting --> Terminated; At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.
- | oxandrolone / Generic mfg.
New P1/2 trial: Use of Oxandrolone to Promote Growth in Infants With HLHS (clinicaltrials.gov) - Sep 15, 2019
P1/2, N=100, Not yet recruiting, Sponsor: New England Research Institutes
- | oxandrolone / Generic mfg.
Enrollment open: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Jun 24, 2019
P2, N=144, Recruiting, Sponsor: University of Southern California
We are unable to submit the results-data. Not yet recruiting --> Recruiting
- | oxandrolone / Generic mfg.
Enrollment change, Trial withdrawal: RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone (clinicaltrials.gov) - Apr 19, 2019
P2, N=0, Withdrawn, Sponsor: Denver Health and Hospital Authority
Not yet recruiting --> Recruiting N=40 --> 0 | Completed --> Withdrawn
- | oxandrolone / Generic mfg.
Trial completion, Trial primary completion date: Oxandrolone in Healthy Adults: A Relative Bioavailability Study (clinicaltrials.gov) - May 3, 2018
P1, N=6, Completed, Sponsor: University of Utah
N=40 --> 0 | Completed --> Withdrawn Recruiting --> Completed | Trial primary completion date: Aug 2017 --> Nov 2017
- | oxandrolone / Generic mfg.
Trial initiation date, Trial primary completion date: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Jan 17, 2018
P2, N=144, Not yet recruiting, Sponsor: University of Southern California
Recruiting --> Completed | Trial primary completion date: Aug 2017 --> Nov 2017 Initiation date: Oct 2017 --> May 2018 | Trial primary completion date: Jul 2020 --> Dec 2020
- | oxandrolone / Generic mfg.
Trial completion: RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone (clinicaltrials.gov) - Jan 12, 2018
P2, N=40, Completed, Sponsor: Denver Health and Hospital Authority
Initiation date: Oct 2017 --> May 2018 | Trial primary completion date: Jul 2020 --> Dec 2020 Recruiting --> Completed
- | oxandrolone / Generic mfg.
Trial initiation date: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Aug 3, 2017
P2, N=144, Not yet recruiting, Sponsor: University of Southern California
Recruiting --> Completed Initiation date: Jun 2017 --> Oct 2017
- | NN1213 / Novo Nordisk
Trial completion: The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome (clinicaltrials.gov) - Jun 30, 2017
P2, N=80, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Initiation date: Jun 2017 --> Oct 2017 No longer recruiting --> Completed
- | oxandrolone / Generic mfg.
Trial primary completion date: Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation (clinicaltrials.gov) - May 31, 2017
P2/3, N=1100, Recruiting, Sponsor: The University of Texas Medical Branch, Galveston
No longer recruiting --> Completed Trial primary completion date: Sep 2017 --> Sep 2018
- | oxandrolone / Generic mfg.
New P2 trial: Oxandrolone Rotator Cuff Trial (clinicaltrials.gov) - Mar 27, 2017
P2, N=144, Not yet recruiting, Sponsor: University of Southern California
- oxandrolone / Generic mfg.
Enrollment closed, Surgery: Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants (clinicaltrials.gov) - Jan 10, 2017
P1, N=20, Active, not recruiting, Sponsor: University of Utah
Trial primary completion date: Sep 2017 --> Sep 2018 Recruiting --> Active, not recruiting
- oxandrolone / Generic mfg.
Trial primary completion date: RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone (clinicaltrials.gov) - Nov 18, 2016
P2, N=40, Recruiting, Sponsor: Denver Health and Hospital Authority
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- oxandrolone / Generic mfg.
Enrollment open, Trial initiation date: RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone (clinicaltrials.gov) - May 6, 2016
P2, N=40, Recruiting, Sponsor: Denver Health and Hospital Authority
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jan 2015
- | oxandrolone / Generic mfg.
Enrollment change: Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation (clinicaltrials.gov) - Dec 5, 2015
P2/3, N=1100, Recruiting, Sponsor: The University of Texas Medical Branch, Galveston
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Jan 2015 N=900 --> 1100
- oxandrolone / Generic mfg.
Enrollment open, Enrollment change, Trial primary completion date, Surgery: Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants (clinicaltrials.gov) - Sep 24, 2015
P1, N=20, Recruiting, Sponsor: University of Utah
N=900 --> 1100 Completed --> Recruiting | N=10 --> 20 | Trial primary completion date: May 2012 --> May 2018
- oxandrolone / Generic mfg.
Trial initiation date, Trial primary completion date: RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone (clinicaltrials.gov) - Jul 8, 2015
P2, N=40, Not yet recruiting, Sponsor: Denver Health and Hospital Authority
Completed --> Recruiting | N=10 --> 20 | Trial primary completion date: May 2012 --> May 2018 Initiation date: Apr 2015 --> Apr 2016 | Trial primary completion date: Dec 2015 --> Dec 2016
- | oxandrolone / Generic mfg.
Trial completion: Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD) (clinicaltrials.gov) - Mar 23, 2015
P=N/A, N=160, Completed, Sponsor: FDA Office of Orphan Products Development
Initiation date: Apr 2015 --> Apr 2016 | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed
- oxandrolone / Generic mfg.
Trial initiation date, Trial primary completion date: RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone (clinicaltrials.gov) - Nov 25, 2014
P2, N=40, Not yet recruiting, Sponsor: Denver Health and Hospital Authority
Recruiting --> Completed Initiation date: Apr 2014 --> Apr 2015 | Trial primary completion date: Dec 2014 --> Dec 2015
- | oxandrolone / Generic mfg.
Trial completion: Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome (clinicaltrials.gov) - Feb 19, 2014
P2, N=80, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Initiation date: Apr 2014 --> Apr 2015 | Trial primary completion date: Dec 2014 --> Dec 2015 No longer recruiting --> Completed
- oxandrolone / Generic mfg.
New P2 trial: RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone (clinicaltrials.gov) - Jan 26, 2014
P2, N=40, Not yet recruiting, Sponsor: Denver Health and Hospital Authority